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 Glaucoma is a term used to describe a group of disorders
that have optic neuropathy as a common feature. Optic neur-
opathy is optic nerve head cupping or degeneration of the op-
tic nerve. This cupping of the optic nerve head initially leads
to the loss of peripheral vision and, if not treated in time, re-
sults in irreversible blindness [1]. Among the different forms
of glaucoma, the primary open angle glaucoma (POAG) is
the most common type [2,3]. There are two forms of POAG:
adult onset and juvenile onset. These are mainly distinguished
based on the age of onset of the disease. However, juvenile
onset POAG usually has a more severe disease phenotype com-
pared to the adult onset type [2,4].
India has a high prevalence of glaucoma with POAG be-
ing the most common form of glaucoma [5]. In the WHO re-
port on the prevalence of glaucoma in India, 1% of the popu-
lation was stated to be blind of which 12.8% was due to glau-
coma [6]. The prevalence of POAG in South Indian popula-
tions has been reported to be 1.62% [7,8]. This prevalence
rate is similar to that observed in Western populations.
A family history of glaucoma has long been recognized
as an important risk factor for the disease. The common adult
onset POAG is inherited as a complex trait, while the juvenile
onset POAG exhibits autosomal dominant mode of inherit-
ance [9]. The prevalence of POAG among first degree rela-
tives of affected patients is as high as 16-22% [10,11]. Thus
far, 22 gene loci have been linked to POAG [9,12-26].
Three genes, MYOC, OPTN, and WDR 36, have been
found to mutate among POAG patients [23,27,28]. The MYOC
gene, located on the GLC1A locus, was initially known as the
trabecular meshwork-inducible glucocorticoid response
(TIGR) gene. MYOC sequence variations associated with
POAG were first observed by Stone et al. [27]. Mutations in
the MYOC gene have now been reported to be present among
POAG patients from almost all parts of the world [1,29-41].
An average mutation frequency of 1.4-4.6% has been observed
among POAG patients worldwide [29,32,35,42]. The MYOC
gene consists of three exons with two intervening introns. Exon
III is the largest of the three and is referred to as the
olfactomedin-like domain due to its homology to olfactomedin.
More than 90% of the mutations reported so far are clustered
to exon III of the gene [34,43].
There are three reports currently available on populations
from different parts of India that estimate the mutation fre-
quency among randomly selected, unrelated POAG patients.
Sripriya et al. [40] reported a mutation frequency of 2% among
100 patients screened from Chennai (South India). Kanagavalli
et al. [39] found a mutation frequency of 2% among 107 POAG
patients screened from Madurai (South India). While
Mukhopadhyay et al. [36] reported mutations among 4 of 56
POAG patients (about 7.1%) screened from Kolkata (East In-
dia).
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Purpose: Glaucoma can be defined as optic neuropathy leading to irreversible blindness if not treated in time. Primary
open angle glaucoma (POAG) is the most common form of glaucoma. The myocilin (MYOC) gene has been found to
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MYOC gene was screened using the PCR-SSCP methodology followed by DNA sequencing. The sequences were ana-
lyzed using BLAST. Secondary structures of the amino acid sequences with a variation were predicted.
Results: Two probable disease-causing variations (mutations), Ser331Thr and Pro370Leu, were each observed in one
patient apiece. Two polymorphisms, (Tyr347Tyr and Thr325Thr) were also observed in the patients. Ser331Thr is a novel
conservative change while Pro370Leu is a widely reported mutation with an associated severe disease phenotype.
Conclusions: The presence of the mutations in the patients suggests the causative role of the MYOC gene among POAG
patients in the Kanyakumari district of India. The mutation frequency of 2% corresponds well with the other reports from
India and other countries. However, the mutation rate reported from a population in the eastern part of India was much
higher. Screening of patients from different parts of India is essential to estimate the overall mutation frequency. More
functional studies on the MYOC gene are required to elucidate the pathophysiology of POAG.
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497There are two major reasons to screen a gene for muta-
tions: (a) to implicate the gene as a cause of a particular dis-
ease; and (b) to identify as many mutations as possible for the
purpose of understanding genotype-phenotype relationships,
comparing mutation profiles in different populations or con-
structing practical genetic tests for clinical use [34]. The present
study was aimed to implicate or rule out the involvement of
mutations in the MYOC gene in disease causation among
POAG patients of the Kanyakumari district of South India.
This region has never been included in any such genetic or
epidemiological study pertaining to POAG. This study would
serve as an initiator for further POAG research.
METHODS
Clinical Samples:  This study recruited 100 patients from hos-
pitals in the Kanyakumari District. All patients had been given
the diagnosis of adult/juvenile-onset POAG. Eighty-seven of
these were adult onset cases, and 13 were patients with juve-
nile onset open angle glaucoma. Twenty-five patients had at
least one family member affected by POAG. In three cases,
the family history could not be confirmed. An equal number
of age- and sex-matched controls from the same district were
included in the study. Informed consent was obtained from
each individual before blood was drawn. Each patient under-
went a complete ophthalmic examination, which consisted of
measurement of intraocular pressure (IOP), gonioscopic evalu-
ation of the angle, examination and documentation of the op-
tic disc, and visual field testing. The criteria for diagnosing
glaucoma, based on previous reports [4], were that the patient
had been (1) treated for glaucoma prior to their involvement
in the study or (2) had at least two of these features: (a) an IOP
of greater than or equal to 22 mmHg, (b) an increased optic
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TABLE 1. PCR AMPLIFICATION CONDITIONS
The following are given for each primer set: primer name, sequence, binding site, annealing temperature, and expected amplicon size for each
primer set. The asterisk indicates the annealing temperature (Ta).
498cup to disc ratio (where the normal value is 0.3, and glauco-
matous cupping is greater than or equal to 0.5), and (c) visual
field abnormalities with no other apparent cause for the loss
in vision.
Classification of adult and the juvenile onset POAG was
based on age of disease onset; adult onset was considered to
be after 40 years of age, whereas juvenile onset was before
this age [4,9].
Analysis of the MYOC gene: Genomic DNA was isolated
from the blood samples of patients and controls using the salt-
ing out method of Miller et al. [44]. Eight primer sets were
designed to amplify the gene in fragments of <300 bp (Table
1) so as to enable analysis of the amplicons using the single
strand conformation polymorphism methodology. PCR am-
plifications were carried out in 20 µl reaction volumes con-
taining about 100 ng of genomic DNA, 5 pmol of each primer
(forward and reverse), 2 mM of each dNTP, 0.5 U of Taq poly-
merase with a standard buffer containing 1.5 mM MgCl2.
Amplification was carried out under the following conditions:
initial denaturation 94 °C for 5 min, followed by 30 cycles of
denaturation 94 °C for 30 s, annealing for 30 s (for each an-
nealing temperature [Ta], please Refer to Table 1), extension -
72 °C for 30 s, followed by a final extension at 72 °C for 2
min.
The amplicons were mixed with the loading dye (bro-
mophenol blue, xylene cyanol, formamide, and Na2EDTA) and
double distilled water in the following ratio: 2 µl amplicon, 2
µl dye, and 16 µl double distilled water. The combination was
heat denatured for 5 min in boiling water and electrophoresed
on a composite (acrylamide, bis acrylamide, and agarose) gel
[45] for 13 to 14 h. The percentage of the gels used and the
electrophoresis voltage varied for amplicons of the different
primers sets. Gels were silver stained as per the protocol of
Bassam et al. [46]. The amplicons with a mobility shift were
reamplified, column purified, and sequenced using dye termi-
nation chemistry and read using the 96 capillary 3730x1 DNA
analyzer (Applied Biosystems, Foster City, CA). Sequences
were analyzed using BLAST to identify the variation(s).
DNA sequences with a variation were translated in silico
to obtain the corresponding amino acid sequences. The amino
acid sequences were subjected to the secondary structure pre-
diction using the Garnier-Osguthorpe-Robson (GOR) predic-
tion method [47,48], a means of predicting the secondary struc-
ture of proteins. This method forecasts the secondary struc-
ture of a sequence by calculating the probability for each of
the four structure classes (helix, sheet, turn, and loop) based
on the central residue and its neighbors from the precalculated
matrices. The highest is then selected for each residue.
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Figure 1. Heterozygous Ser331Thr mutation and Thr325Thr poly-
morphism in the MYOC gene.  Chromatogram sequence derived from
patient Ngl 12 with the T>A transversion and G>A transition (indi-
cated by arrows) compared to the normal control.
Figure 2. Heterozygous Pro370Leu mutation in the MYOC gene.
Comparison of chromatogram sequences derived from patient R6
and normal control. Arrow marks the C>T transition compared to the
normal control.
499RESULTS
 Four different types of sequence variations were obtained.
Two of these were nonsynonymous mutations i.e., the varia-
tions were both in the nucleotide sequence, and the correspond-
ing amino acid sequence (missense mutation), namely
Ser331Thr and Pro370Leu, showed up in at least one patient
(Figure 1 and Figure 2). These were probable disease-causing
variations. The other two were synonymous variations, mean-
ing the changes were in the nucleotide sequence alone and not
in the corresponding amino acid sequence: (1) Tyr347Tyr in
four patients and (2) Thr325Thr in one patient. All sequence
variations were observed in the heterozygous state and only
in the patients’ samples.
The Ser331Thr mutation (T>A transversion at nucleotide
991) was observed in one patient, who also had the Thr325Thr
synonymous mutation (G>A transition at nucleotide 975). This
patient was 68 years old at the time of sample collection. At
the time of blood drawing the patient’s IOP was 20.6 mmHg
OD and 20.6 mmHg OS. The patient was was being treated
with 0.5% levobunolol for POAG. The cup to disc ratio re-
vealed a totally excavated disc in the left eye and was 0.9 in
the right eye. The left eye was totally blind with only light
perception, and the right eye had about 25° of vision. The pa-
tient was hypertensive (180/100 mmHg). The patient denied a
family history of the disease.
The Pro370Leu (C>T transition at nucleotide 1109) was
the other mutation observed in one patient only. The patient
was 57 years old at the time of sample collection and she had
been affected by glaucoma at about 16 years of age. During
the last stages of her vision, she had highly elevated pressures
(readings not available), open angles, and no other systemic
or ocular abnormalities that could have resulted in the loss of
vision, indicating POAG. This is a typical example of a rapid
progressive JOAG with an early age of onset. It was later
learned she had a family history of glaucoma. Her brother
developed JOAG before the age of 30 and six of her uncles
(distant relatives) developed either POAG or primary angle
closure glaucoma (PACG). Her brother with POAG, three of
her uncles (first cousins once removed), and one second cousin
who had POAG/PACG were also included in the present study.
However, none of them had any variation in the MYOC gene.
The other synonymous variation or polymorphism was
the Tyr347Tyr (1041 T>C) change. This was seen in four pa-
tients.
Random sequencing of five patients and five normal con-
trol samples of each primer set confirmed the negative results
of SSCP analysis.
DISCUSSION
 This is the first such study from this part of India. The pa-
tients from the Kanyakumari district had two mutations: (1)
Pro370Leu (1109 C>T) and (2) Ser331Thr (991 T>A). The
Ser331Thr is a novel mutation with no report of it available at
present as far as our literature search showed. The other muta-
tion has been reported in other populations worldwide.
The Ser331Thr mutation observed in this study is a con-
servative change of serine to threonine. However its absence
in the controls and the effect of this change on the predicted
secondary structure of the protein (Figure 3) suggests that it
might have a causal effect. Alhough there is no direct evi-
dence of this being a causal factor of glaucoma, the benign
nature of this variant cannot be assumed. The fact that this
change is not mentioned in the literature and that it was absent
in the normal controls indicates this is a mutation or a prob-
able disease-causing variation.
An earlier report mentions that though the nonconservative
changes were presumably more injurious to the functioning
of the myocilin protein than conservative changes, the con-
servative changes have also been classified as probable dis-
ease-causing mutations if they were absent in the controls [34].
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Figure 3. Secondary structure prediction of the mutant sequence (Ser331Thr) using the GOR method.  Comparison between the predicted
secondary structures of control (A) amino acid sequences of myocilin and the amino acid sequences of myocilin with the Ser331Thr variant
(B; only the region where there was a change in the predicted secondary structure has been shown).
500The Pro370Leu alteration was observed in one patient,
who had a severe disease phenotype with an early age of on-
set of the disease (diagnosed at 16 years), rapid progression of
the disease, and a positive family history of the disease. The
severe nature of the disease phenotype associated with this
variant correlates well with earlier reports [30,33,49]. The
proband reported by Damji et al. [50] had a similar clinical
history as that of the aforedescribed patient: early age of on-
set, much before sample collection, lack of initial ophthalmo-
logical examination records, and a family history of the dis-
ease.
This mutation has also been reported in an Indian patient
from Kolkata (eastern part of India) [36]. The patient had pres-
sures of 24 mmHg OD and 32 mmHg OS and cup to disc
ratios of 0.8 OD 0.7 OS. Vision tests revealed presence of an
arcuate scotoma in the superior and inferior halves with nasal
steps OD and a scotomatous defect in the superonasal quad-
rant OS.
The occurrence of this mutation in patients of varying
ethnicity (Indian, English, French, North American, Japanese,
and German populations) suggests this is a prevalent mutant
allele of MYOC. The severe nature of the disease in patients
with this mutation indicates that the loss of proline at this po-
sition may acutely affect the normal function of the protein
[32]. However, further studies are needed to correlate disease
severity with this mutation.
The change C>T transition at nucleotide 1109, results in
a change from proline (a polar amino acid) to a hydrophobic
leucine molecule. This transition occurs in the CpG dinucle-
otide. The importance of CpGs in the disease causation was
suggested by Mukhopodhyay, et al. [36].
The translationally silent polymorphism in codon 347 has
a relatively high incidence in subjects from the Kanyakumari
district (about 4%). These observations indicate this is a fre-
quent polymorphism found among POAG patients of this part
of India.
Both the mutations presented here have been predicted to
affect the myocilin protein’s secondary structure. Secondary
structure prediction of the Ser331Thr mutant amino acid se-
quence by GOR revealed a removal of turn “T” at the amino
acid 332 followed by an addition of a β sheet “E” at amino
acid 332 and 333. A substitution of β sheet “E” to turn “T” at
amino acid 325 was predicted and β sheet “E” was expected
to coil “C” at 337. The Pro370Leu results in a change from a
polar amino acid to a hydrophobic amino acid. This mutation
also results in changes in the predicted secondary structure.
Moreover, it has been elucidated that proline has a side chain
that inhibits (α helix) formation and fits poorly in the α helix
conformation, while leucine is one of the good α helix form-
ers [51]. Since the function of the TIGR/MYOC gene has not
yet been fully elucidated, the effects of single amino acid
changes cannot be precisely predicted and can only be hy-
pothesized [52].
The findings suggest that the MYOC gene is involved in
the causation of POAG in this part of India as well. The muta-
tion rate was 2% among POAG patients of the Kanyakumari
district This is not a high rate, but the frequency coincides
with that reported from other parts of India and the world.
A larger data set including more patients and functional
studies on the MYOC gene are required to elucidate the patho-
physiology of POAG.
ACKNOWLEDGEMENTS
 We wish to sincerely thank Dr. Bejan Singh, Dr. Rooshita
Bejan Singh, and Dr. Hector. This work was supported by
Council of Scientific and Industrial Research in the form of a
Senior Research Fellowship. We thank the patients, their fam-
ily members, and the control subjects for participating in this
study.
REFERENCES
 1. Ikezoe T, Takeuchit S, Komatsu N, Okada M, Fukushima A, Ueno
H, Koeffler HP, Taguchi H. Identification of a new GLC1A
mutation in a sporadic, primary open-angle glaucoma in Japan.
Int J Mol Med 2003; 12:259-61.
2. Raymond V. Molecular genetics of the glaucomas: mapping of the
first five “GLC” loci. Am J Hum Genet 1997; 60:272-7.
3. Khaw PT, Shah P, Elkington AR. Glaucoma—1: diagnosis. BMJ
2004; 328:97-9. Erratum in: BMJ. 2004; 328:762.
4. Morissette J, Cote G, Anctil JL, Plante M, Amyot M, Heon E,
Trope GE, Weissenbach J, Raymond V. A common gene for
juvenile and adult-onset primary open-angle glaucomas con-
fined on chromosome 1q. Am J Hum Genet 1995; 56:1431-42.
5. Balasubramanian D. Molecular and cellular approaches to under-
stand and treat some diseases of the eye. Curr Sci 2002; 82:
948-957.
6. Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Global
data on blindness. Bull World Health Organ 1995; 73:115-21.
7. Dandona L, Dandona R, Srinivas M, Mandal P, John RK, McCarty
CA, Rao GN. Open-angle glaucoma in an urban population in
southern India: the Andhra Pradesh eye disease study. Ophthal-
mology 2000; 107:1702-9.
8. Vijaya L, George R, Paul PG, Baskaran M, Arvind H, Raju P,
Ramesh SV, Kumaramanickavel G, McCarty C. Prevalence of
open-angle glaucoma in a rural south Indian population. Invest
Ophthalmol Vis Sci 2005; 46:4461-7.
9. Wiggs JL, Lynch S, Ynagi G, Maselli M, Auguste J, Del Bono EA,
Olson LM, Haines JL. A genomewide scan identifies novel early-
onset primary open-angle glaucoma loci on 9q22 and 20p12.
Am J Hum Genet 2004; 74:1314-20.
10. Wolfs RC, Klaver CC, Ramrattan RS, van Duijn CM, Hofman A,
de Jong PT. Genetic risk of primary open-angle glaucoma. Popu-
lation-based familial aggregation study. Arch Ophthalmol 1998;
116:1640-5.
11. Alward WL. The genetics of open-angle glaucoma: the story of
GLC1A and myocilin. Eye 2000; 14:429-36.
12. Fan BJ, Wang DY, Lam DS, Pang CP. Gene mapping for primary
open angle glaucoma. Clin Biochem 2006; 39:249-58.
13. Sripriya S, Nirmaladevi J, George R, Hemamalini A, Baskaran
M, Prema R, Ve Ramesh S, Karthiyayini T, Amali J, Job S, Vijaya
L, Kumaramanickavel G. OPTN gene: profile of patients with
glaucoma from India. Mol Vis 2006; 12:816-20.
14. Pang CP, Fan BJ, Canlas O, Wang DY, Dubois S, Tam PO, Lam
DS, Raymond V, Ritch R. A genome-wide scan maps a novel
juvenile-onset primary open angle glaucoma locus to chromo-
some 5q. Mol Vis 2006; 12:85-92.
15. Wang DY, Fan BJ, Chua JK, Tam PO, Leung CK, Lam DS, Pang
CP. A Genome-wide Scan Maps a Novel Juvenile-Onset Pri-
©2007 Molecular Vision Molecular Vision 2007; 13:497-503 <http://www.molvis.org/molvis/v13/a53/>
501mary Open-Angle Glaucoma Locus to 15q. Invest Ophthalmol
Vis Sci 2006; 47:5315-21.
16. Sheffield VC, Stone EM, Alward WL, Drack AV, Johnson AT,
Streb LM, Nichols BE. Genetic linkage of familial open angle
glaucoma to chromosome 1q21-q31. Nat Genet 1993; 4:47-50.
17. Stoilova D, Child A, Trifan OC, Crick RP, Coakes RL, Sarfarazi
M. Localization of a locus (GLC1B) for adult-onset primary
open angle glaucoma to the 2cen-q13 region. Genomics 1996;
36:142-50.
18. Wirtz MK, Samples JR, Kramer PL, Rust K, Topinka JR, Yount
J, Koler RD, Acott TS. Mapping a gene for adult-onset primary
open-angle glaucoma to chromosome 3q. Am J Hum Genet 1997;
60:296-304.
19. Trifan OC, Traboulsi EI, Stoilova D, Alozie I, Nguyen R, Raja S,
Sarfarazi M. A third locus (GLC1D) for adult-onset primary
open-angle glaucoma maps to the 8q23 region. Am J Ophthalmol
1998; 126:17-28.
20. Sarfarazi M, Child A, Stoilova D, Brice G, Desai T, Trifan OC,
Poinoosawmy D, Crick RP. Localization of the fourth locus
(GLC1E) for adult-onset primary open-angle glaucoma to the
10p15-p14 region. Am J Hum Genet 1998; 62:641-52.
21. Wirtz MK, Samples JR, Rust K, Lie J, Nordling L, Schilling K,
Acott TS, Kramer PL. GLC1F, a new primary open-angle glau-
coma locus, maps to 7q35-q36. Arch Ophthalmol 1999; 117:237-
41.
22. Kitsos G, Eiberg H, Economou-Petersen E, Wirtz MK, Kramer
PL, Aspiotis M, Tommerup N, Petersen MB, Psilas K. Genetic
linkage of autosomal dominant primary open angle glaucoma
to chromosome 3q in a Greek pedigree. Eur J Hum Genet 2001;
9:452-7.
23. Monemi S, Spaeth G, DaSilva A, Popinchalk S, Ilitchev E,
Liebmann J, Ritch R, Heon E, Crick RP, Child A, Sarfarazi M.
Identification of a novel adult-onset primary open-angle glau-
coma (POAG) gene on 5q22.1. Hum Mol Genet 2005; 14:725-
33.
24. Allingham RR, Wiggs JL, Hauser ER, Larocque-Abramson KR,
Santiago-Turla C, Broomer B, Del Bono EA, Graham FL, Haines
JL, Pericak-Vance MA, Hauser MA. Early adult-onset POAG
linked to 15q11-13 using ordered subset analysis. Invest
Ophthalmol Vis Sci 2005; 46:2002-5.
25. Wiggs JL, Allingham RR, Hossain A, Kern J, Auguste J, DelBono
EA, Broomer B, Graham FL, Hauser M, Pericak-Vance M,
Haines JL. Genome-wide scan for adult onset primary open angle
glaucoma. Hum Mol Genet 2000; 9:1109-17.
26. Lemmela S, Ylisaukko-oja T, Forsman E, Jarvela I. Exclusion of
14 candidate loci for primary open angle glaucoma in Finnish
families. Mol Vis 2004; 10:260-4.
27. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR,
Sunden SL, Nishimura D, Clark AF, Nystuen A, Nichols BE,
Mackey DA, Ritch R, Kalenak JW, Craven ER, Sheffield VC.
Identification of a gene that causes primary open angle glau-
coma. Science 1997; 275:668-70.
28. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados
M, Heon E, Krupin T, Ritch R, Kreutzer D, Crick RP, Sarfarazi
M. Adult-onset primary open-angle glaucoma caused by muta-
tions in optineurin. Science 2002; 295:1077-9.
29. Pang CP, Leung YF, Fan B, Baum L, Tong WC, Lee WS, Chua
JK, Fan DS, Liu Y, Lam DS. TIGR/MYOC gene sequence al-
terations in individuals with and without primary open-angle
glaucoma. Invest Ophthalmol Vis Sci 2002; 43:3231-5.
30. Adam MF, Belmouden A, Binisti P, Brezin AP, Valtot F,
Bechetoille A, Dascotte JC, Copin B, Gomez L, Chaventre A,
Bach JF, Garchon HJ. Recurrent mutations in a single exon en-
coding the evolutionarily conserved olfactomedin-homology
domain of TIGR in familial open-angle glaucoma. Hum Mol
Genet 1997; 6:2091-7.
31. Alward WL, Fingert JH, Coote MA, Johnson AT, Lerner SF,
Junqua D, Durcan FJ, McCartney PJ, Mackey DA, Sheffield
VC, Stone EM. Clinical features associated with mutations in
the chromosome 1 open-angle glaucoma gene (GLC1A). N Engl
J Med 1998; 338:1022-7.
32. Wiggs JL, Allingham RR, Vollrath D, Jones KH, De La Paz M,
Kern J, Patterson K, Babb VL, Del Bono EA, Broomer BW,
Pericak-Vance MA, Haines JL. Prevalence of mutations in TIGR/
Myocilin in patients with adult and juvenile primary open-angle
glaucoma. Am J Hum Genet 1998; 63:1549-52.
33. Rozsa FW, Shimizu S, Lichter PR, Johnson AT, Othman MI, Scott
K, Downs CA, Nguyen TD, Polansky J, Richards JE. GLC1A
mutations point to regions of potential functional importance
on the TIGR/MYOC protein. Mol Vis 1998; 4:20.
34. Fingert JH, Heon E, Liebmann JM, Yamamoto T, Craig JE, Rait
J, Kawase K, Hoh ST, Buys YM, Dickinson J, Hockey RR,
Williams-Lyn D, Trope G, Kitazawa Y, Ritch R, Mackey DA,
Alward WL, Sheffield VC, Stone EM. Analysis of myocilin
mutations in 1703 glaucoma patients from five different popu-
lations. Hum Mol Genet 1999; 8:899-905.
35. Yoon SJ, Kim HS, Moon JI, Lim JM, Joo CK. Mutations of the
TIGR/MYOC gene in primary open-angle glaucoma in Korea.
Am J Hum Genet 1999; 64:1775-8.
36. Mukhopadhyay A, Acharya M, Mukherjee S, Ray J, Choudhury
S, Khan M, Ray K. Mutations in MYOC gene of Indian pri-
mary open angle glaucoma patients. Mol Vis 2002; 8:442-8.
37. Faucher M, Anctil JL, Rodrigue MA, Duchesne A, Bergeron D,
Blondeau P, Cote G, Dubois S, Bergeron J, Arseneault R,
Morissette J, Raymond V, Quebec Glaucoma Network. Founder
TIGR/myocilin mutations for glaucoma in the Quebec popula-
tion. Hum Mol Genet 2002; 11:2077-90.
38. Alward WL, Kwon YH, Khanna CL, Johnson AT, Hayreh SS,
Zimmerman MB, Narkiewicz J, Andorf JL, Moore PA, Fingert
JH, Sheffield VC, Stone EM. Variations in the myocilin gene in
patients with open-angle glaucoma. Arch Ophthalmol 2002;
120:1189-97.
39. Kanagavalli J, Krishnadas SR, Pandaranayaka E, Krishnaswamy
S, Sundaresan P. Evaluation and understanding of myocilin
mutations in Indian primary open angle glaucoma patients. Mol
Vis 2003; 9:606-14.
40. Sripriya S, Uthra S, Sangeetha R, George RJ, Hemamalini A,
Paul PG, Amali J, Vijaya L, Kumaramanickavel G. Low fre-
quency of myocilin mutations in Indian primary open-angle glau-
coma patients. Clin Genet 2004; 65:333-7.
41. Ishikawa K, Funayama T, Ohtake Y, Tanino T, Kurosaka D, Suzuki
K, Ideta H, Fujimaki T, Tanihara H, Asaoka R, Naoi N, Yasuda
N, Iwata T, Mashima Y. Novel MYOC gene mutation,
Phe369Leu, in Japanese patients with primary open-angle glau-
coma detected by denaturing high-performance liquid chroma-
tography. J Glaucoma 2004; 13:466-71.
42. Aldred MA, Baumber L, Hill A, Schwalbe EC, Goh K,
Karwatowski W, Trembath RC. Low prevalence of MYOC
mutations in UK primary open-angle glaucoma patients limits
the utility of genetic testing. Hum Genet 2004; 115:428-31.
43. Markandaya M, Ramesh TK, Selvaraju V, Dorairaj SK, Prakash
R, Shetty J, Kumar A. Genetic analysis of an Indian family with
members affected with juvenile-onset primary open-angle glau-
coma. Ophthalmic Genet 2004; 25:11-23.
44. Miller SA, Dykes DD, Polesky HF. A simple salting out proce-
dure for extracting DNA from human nucleated cells. Nucleic
©2007 Molecular Vision Molecular Vision 2007; 13:497-503 <http://www.molvis.org/molvis/v13/a53/>
502Acids Res 1988; 16:1215.
45. Peng H, Du M, Ji J, Isaacson PG, Pan L. High-resolution SSCP
analysis using polyacrylamide agarose composite gel and a back-
ground-free silver staining method. Biotechniques 1995; 19:410-
4.
46. Bassam BJ, Caetano-Anolles G, Gresshoff PM. Fast and sensi-
tive silver staining of DNA in polyacrylamide gels. Anal
Biochem 1991; 196:80-3. Erratum in: Anal Biochem 1991;
198:217.
47. Garnier J, Osguthorpe DJ, Robson B. Analysis of the accuracy
and implications of simple methods for predicting the second-
ary structure of globular proteins. J Mol Biol 1978; 120:97-120.
48. Garnier J, Gibrat JF, Robson B. GOR method for predicting pro-
tein secondary structure from amino acid sequence. Methods
Enzymol 1996; 266:540-53.
49. Taniguchi F, Suzuki Y, Shirato S, Ohta S. Clinical phenotype of a
Japanese family with primary open angle glaucoma caused by a
Pro370Leu mutation in the MYOC/TIGR gene. Jpn J
Ophthalmol 1999; 43:80-4.
50. Damji KF, Song X, Gupta SK, Gao J, Rock W, Bulman DE. Child-
hood-onset primary open angle glaucoma in a Canadian kin-
dred: clinical and molecular genetic features. Ophthalmic Genet
1999; 20:211-8.
51. Brandon C, Tooze J. Introduction to protein structure. 2nd ed.
New York: Garland Publishing Inc; 1999. Chapter 1. p 3-30.
52. Michels-Rautenstrauss KG, Mardin CY, Budde WM, Liehr T,
Polansky J, Nguyen T, Timmerman V, Van Broeckhoven C,
Naumann GO, Pfeiffer RA, Rautenstrauss BW. Juvenile open
angle glaucoma: fine mapping of the TIGR gene to 1q24.3-q25.2
and mutation analysis. Hum Genet 1998; 102:103-6.
©2007 Molecular Vision Molecular Vision 2007; 13:497-503 <http://www.molvis.org/molvis/v13/a53/>
503
The print version of this article was created on 2 Apr 2007. This reflects all typographical corrections and errata to the article through that date.
Details of any changes may be found in the online version of the article. α